Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Livedoid and Purpuric Skin Eruptions Associated With Coagulopathy in Severe COVID-19.

Literature DB >> 32756881

Livedoid and Purpuric Skin Eruptions Associated With Coagulopathy in Severe COVID-19.

Caren Droesch¹, Mytrang Hoang Do¹, Maria DeSancho², Eun-Ju Lee², Cynthia Magro³, Joanna Harp¹.

Abstract

Entities: Chemical

Mesh：

Year: 2020 PMID： 32756881 PMCID： PMC7376463 DOI： 10.1001/jamadermatol.2020.2800

Source DB: PubMed Journal: JAMA Dermatol ISSN： 2168-6068 Impact factor: 10.282

× No keyword cloud information.

35 in total

1. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal: J Clin Epidemiol Date: 2008-04 Impact factor: 6.437

2. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.

Authors: Khalaf Kridin; Reuven Bergman
Journal: JAMA Dermatol Date: 2018-10-01 Impact factor: 10.282

3. Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes.

Authors: Antonios Douros; Julie Rouette; Hui Yin; Oriana Hoi Yun Yu; Kristian B Filion; Laurent Azoulay
Journal: Diabetes Care Date: 2019-06-10 Impact factor: 19.112

Review 4. Do DPP-4 Inhibitors Cause Heart Failure Events by Promoting Adrenergically Mediated Cardiotoxicity? Clues From Laboratory Models and Clinical Trials.

Authors: Milton Packer
Journal: Circ Res Date: 2018-02-07 Impact factor: 17.367

Review 5. Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases.

Authors: Annamaria Mascolo; Concetta Rafaniello; Liberata Sportiello; Maurizio Sessa; Daniela Cimmaruta; Francesco Rossi; Annalisa Capuano
Journal: Drug Saf Date: 2016-05 Impact factor: 5.606

6. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin.

Authors: K Skandalis; M Spirova; G Gaitanis; A Tsartsarakis; I D Bassukas
Journal: J Eur Acad Dermatol Venereol Date: 2011-04-06 Impact factor: 6.166

7. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database.

Authors: J Béné; G Moulis; I Bennani; M Auffret; P Coupe; S Babai; D Hillaire-Buys; J Micallef; S Gautier
Journal: Br J Dermatol Date: 2016-07-19 Impact factor: 9.302

8. Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes.

Authors: Olga Montvida; Jonathan Shaw; John J Atherton; Frances Stringer; Sanjoy K Paul
Journal: Diabetes Care Date: 2017-11-06 Impact factor: 19.112

9. Incidence of bullous pemphigoid in Sweden 2005-2012: a nationwide population-based cohort study of 3761 patients.

Authors: Kristofer Thorslund; Oliver Seifert; Karin Nilzén; Carina Grönhagen
Journal: Arch Dermatol Res Date: 2017-09-05 Impact factor: 3.017

10. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.

Authors: Peter C Austin
Journal: Stat Med Date: 2009-11-10 Impact factor: 2.373

15 in total

Review 1. Getting to the Heart of the Matter: Myocardial Injury, Coagulopathy, and Other Potential Cardiovascular Implications of COVID-19.

Authors: Aaron Schmid; Marija Petrovic; Kavya Akella; Anisha Pareddy; Sumathilatha Sakthi Velavan
Journal: Int J Vasc Med Date: 2021-04-22

2. Unilateral livedo reticularis in COVID-19 patient: Case with fatal outcome.

Authors: Ivana Tusheva; Katerina Damevska; Irena Dimitrovska; Zorica Markovska; Liljana Malinovska-Nikolovska
Journal: JAAD Case Rep Date: 2020-11-05

Review 3. Skin Manifestations Associated with COVID-19: Current Knowledge and Future Perspectives.

Authors: Giovanni Genovese; Chiara Moltrasio; Emilio Berti; Angelo Valerio Marzano
Journal: Dermatology Date: 2020-11-24 Impact factor: 5.366

4. The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 - A systematic review of the literature.

Authors: Lucia Novelli; Francesca Motta; Maria De Santis; Aftab A Ansari; M Eric Gershwin; Carlo Selmi
Journal: J Autoimmun Date: 2020-12-14 Impact factor: 7.094

Review 5. Cutaneous Manifestations in Confirmed COVID-19 Patients: A Systematic Review.

Authors: Claudio Conforti; Caterina Dianzani; Marina Agozzino; Roberta Giuffrida; Giovanni Francesco Marangi; Nicola di Meo; Silviu-Horia Morariu; Paolo Persichetti; Francesco Segreto; Iris Zalaudek; Nicoleta Neagu
Journal: Biology (Basel) Date: 2020-12-05

Review 6. COVID-19: immunopathology, pathophysiological mechanisms, and treatment options.

Authors: Larissa E van Eijk; Mathijs Binkhorst; Arno R Bourgonje; Annette K Offringa; Douwe J Mulder; Eelke M Bos; Nikola Kolundzic; Amaal E Abdulle; Peter Hj van der Voort; Marcel Gm Olde Rikkert; Johannes G van der Hoeven; Wilfred Fa den Dunnen; Jan-Luuk Hillebrands; Harry van Goor
Journal: J Pathol Date: 2021-03-25 Impact factor: 9.883

Review 10. Cutaneous Manifestations in Adult Patients with COVID-19 and Dermatologic Conditions Related to the COVID-19 Pandemic in Health Care Workers.

Authors: Stephanie L Mawhirt; David Frankel; Althea Marie Diaz
Journal: Curr Allergy Asthma Rep Date: 2020-10-12 Impact factor: 4.806